Obesity-induced CYP2E1 activity in children.
作者信息
Gade Christina, Dalhoff Kim, Petersen Tonny, Riis Troels, Schmeltz Camilla, Chabanova Elizaveta, Christensen Hanne Rolighed, Mikus Gerd, Burhenne Juergen, Holm Jens Christian, Holst Helle
机构信息
Department of Clinical Pharmacology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark.
The Children's Obesity Clinic, Department of Paediatrics, Copenhagen University Hospital Holbaek, Denmark.
出版信息
Br J Clin Pharmacol. 2019 Feb;85(2):458-459. doi: 10.1111/bcp.13813. Epub 2018 Dec 9.
Abstract
摘要
相似文献
1
Obesity-induced CYP2E1 activity in children.
Br J Clin Pharmacol. 2019 Feb;85(2):458-459. doi: 10.1111/bcp.13813. Epub 2018 Dec 9.
2
CYP2E1 activity and children with obesity: possible confounding factors.
Br J Clin Pharmacol. 2019 Feb;85(2):457. doi: 10.1111/bcp.13769. Epub 2018 Oct 17.
3
Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans.
Pharmacogenetics. 1999 Jun;9(3):377-88. doi: 10.1097/00008571-199906000-00013.
4
Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity.
Clin Pharmacol Ther. 1994 Oct;56(4):359-67. doi: 10.1038/clpt.1994.150.
5
Higher chlorzoxazone clearance in obese children compared with nonobese peers.
Br J Clin Pharmacol. 2018 Aug;84(8):1738-1747. doi: 10.1111/bcp.13602. Epub 2018 Jun 3.
6
Development of a non-high pressure liquid chromatography assay to determine [14C]chlorzoxazone 6-hydroxylase (CYP2E1) activity in human liver microsomes.
Drug Metab Dispos. 1998 Apr;26(4):305-12.
7
Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1.
Pharmacogenetics. 1995 Jun;5(3):143-50. doi: 10.1097/00008571-199506000-00002.
8
Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity.
Drug Metab Dispos. 1997 Dec;25(12):1429-35.
9
Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats.
Biochem Pharmacol. 2007 Jan 1;73(1):155-62. doi: 10.1016/j.bcp.2006.09.006. Epub 2006 Sep 14.
10
Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation.
Fundam Clin Pharmacol. 1998;12(5):553-8. doi: 10.1111/j.1472-8206.1998.tb00985.x.
本文引用的文献
1
CYP2E1 activity and children with obesity: possible confounding factors.
Br J Clin Pharmacol. 2019 Feb;85(2):457. doi: 10.1111/bcp.13769. Epub 2018 Oct 17.
2
Higher chlorzoxazone clearance in obese children compared with nonobese peers.
Br J Clin Pharmacol. 2018 Aug;84(8):1738-1747. doi: 10.1111/bcp.13602. Epub 2018 Jun 3.
3
The CYTONOX trial.
Dan Med J. 2016 May;63(5).
4
Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity.
Br J Clin Pharmacol. 2004 Aug;58(2):190-200. doi: 10.1111/j.1365-2125.2004.02132.x.
5
Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase.
J Hepatol. 2002 Jan;36(1):47-52. doi: 10.1016/s0168-8278(01)00223-9.
6
Cytochrome P-450 2E1 activity and oxidative stress in alcoholic patients.
Alcohol Alcohol. 2000 Jan;35(1):98-103. doi: 10.1093/alcalc/35.1.98.
7
Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans.
Pharmacogenetics. 1999 Jun;9(3):377-88. doi: 10.1097/00008571-199906000-00013.
8
Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans.
Am J Gastroenterol. 1998 Nov;93(11):2154-61. doi: 10.1111/j.1572-0241.1998.00612.x.
9
Cytochrome P-4502E1: its physiological and pathological role.
Physiol Rev. 1997 Apr;77(2):517-44. doi: 10.1152/physrev.1997.77.2.517.
10
Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase.
Alcohol Clin Exp Res. 1995 Apr;19(2):362-6. doi: 10.1111/j.1530-0277.1995.tb01516.x.
Zotero 插件